Literature DB >> 17014019

The management of gout at an academic healthcare center in Beijing: a physician survey.

Weigang Fang1, Xuejun Zeng, Mengtao Li, Lan X Chen, H Ralph Schumacher, Fengchun Zhang.   

Abstract

OBJECTIVE: Gout is a less commonly diagnosed rheumatic disease in China compared with Western countries, but its prevalence appears to be climbing. It is not known how Chinese physicians diagnose and treat their patients with gout, so we evaluated physician management of gout at a major academic healthcare center in Beijing, and investigated factors associated with better decision-making.
METHODS: A 13-question anonymous survey was distributed and collected at a medical grand rounds and then at a rheumatology grand rounds at a major teaching hospital in Beijing. Physician demographic data including educational background, work experience, job titles, specialty or subspecialties, gout patient volume seen in a year, and continuing medical education (CME) in gout were also collected in the survey. Data were analyzed by multivariate regression models to identify factors associated with appropriate answers.
RESULTS: Twenty-seven residents and general internists, 26 rheumatologists and fellows, and 28 physicians and fellows of other medical subspecialties from the Department of Medicine including visiting physicians responded to the survey. Among respondents, 78% think it is important for a definitive diagnosis of gout, but few actually perform aspiration of the affected joint fluid. Eighty-four percent report that they often follow the serum urate level of their patients with diagnosed gout. When treating acute gout in otherwise healthy patients, most physicians (77%) prefer oral colchicine, and in patients with renal impairment, about half of them (48%) choose corticosteroids or corticotropin as their first treatment. For longterm urate-lowering therapy, most physicians (87%) described a variety of indications that we consider less appropriate. They (86%) tend to initiate it early (< 2 weeks) after acute flares. When urate-lowering therapy is used, 80% of physicians sustain it less than 5 years. Further, only 12% of physicians use antiinflammatory prophylaxis during the initiation of urate-lowering treatment, and only 5% maintain it for an appropriate period of time. Logistic regression analysis of physician demographic data, educational background, and work experience found no consistent independent factors associated with better decision-making, other than CME, that were associated with establishing the definite diagnosis correctly. Specifically, the number of gout patients seen by physicians was not related to better decision-making.
CONCLUSION: The physicians' reported management of gout at this major academic healthcare center in Beijing was often inconsistent with current evidence. High quality CME is required to improve Chinese physician management of gout.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17014019

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Why is gout so poorly managed?

Authors:  Eliseo Pascual; Francisca Sivera
Journal:  Ann Rheum Dis       Date:  2007-10       Impact factor: 19.103

2.  Gout treatment: survey of Brazilian rheumatology residents.

Authors:  Rodrigo Balbino Chaves Amorim; Ana Beatriz Vargas-Santos; Leticia Rocha Pereira; Evandro Silva Freire Coutinho; Geraldo da Rocha Castelar-Pinheiro
Journal:  Clin Rheumatol       Date:  2017-01-19       Impact factor: 2.980

3.  Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China.

Authors:  Qian-Hua Li; Lie Dai; Zhao-Xia Li; Hai-Jun Liu; Chan-Juan Zou; Xia Ou-Yang; Meng Lu; Ting Li; Yan-Hua Li; Yin-Qian Mo; H Ralph Schumacher
Journal:  Clin Rheumatol       Date:  2013-07-16       Impact factor: 2.980

Review 4.  Quality of life and quality of care for patients with gout.

Authors:  Jasvinder A Singh
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

5.  Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists.

Authors:  Ana Beatriz Vargas-Santos; Geraldo da Rocha Castelar-Pinheiro; Evandro Silva Freire Coutinho; H Ralph Schumacher; Jasvinder A Singh; Naomi Schlesinger
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

6.  Quality of gout care in the emergency departments: a multicentre study.

Authors:  Patapong Towiwat; Pariwat Phungoen; Kitti Tantrawiwat; Pavita Laohakul; Duangkamol Aiewruengsurat; Chokchai Thanadetsuntorn; Nopparat Ruchakorn; Passagorn Sangsawangchot; Bodin Buttham
Journal:  BMC Emerg Med       Date:  2020-04-20

7.  Rheumatologists' understanding of refractory gout: a questionnaire survey in China.

Authors:  Xinxin Han; Yue Yin; Yu Cao; Xiaotian Chu; Yingdong Han; Hong Di; Na Xu; Yun Zhang; Xuejun Zeng
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

Review 8.  Recent developments in crystal-induced inflammation pathogenesis and management.

Authors:  Frédéric Lioté; Hang-Korng Ea
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

Review 9.  Uricase and other novel agents for the management of patients with treatment-failure gout.

Authors:  John S Sundy; Michael S Hershfield
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.